Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...

Once non-small-cell lung cancer (NSCLC) spreads far and wide, treating it is kind of a balancing act. A cure isn't likely, but you can slow it down. So you aim to relieve your symptoms and improve ...

Plasma-based molecular residual disease analysis shows the potential to predict disease recurrence in lung cancer patients by 4.7 months.

CAN-2409 extended median overall survival to 24.5 months in NSCLC patients, surpassing standard docetaxel chemotherapy outcomes. The treatment showed a significant survival benefit in non-squamous ...

Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive ...

Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its ...

Ivonescimab combined with chemotherapy showed significant progression-free survival benefits in advanced squamous NSCLC patients, including both PD-L1-positive and PD-L1-negative populations. The ...

TUESDAY, March 25, 2025 (HealthDay News) -- For patients with resected stage IB-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer, molecular residual disease (MRD ...

This launch is supported by a large genome-based molecular residual disease (MRD) study ... colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma – Signatera Genome ...